Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial

BACKGROUND: Ticagrelor is a reversibly binding, direct-acting, oral, P(2)Y(12) antagonist used for the prevention of atherothrombotic events in patients with coronary artery disease (CAD). Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) o...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amario, D., Restivo, A., Leone, A. M., Vergallo, R., Migliaro, S., Canonico, F., Galli, M., Trani, C., Burzotta, F., Aurigemma, C., Niccoli, G., Buffon, A., Montone, R. A., Flex, A., Franceschi, F., Tinelli, G., Limbruno, U., Francese, F., Ceccarelli, I., Borovac, J. A., Porto, I., Crea, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027127/
https://www.ncbi.nlm.nih.gov/pubmed/32066489
http://dx.doi.org/10.1186/s13063-020-4116-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027127/
https://www.ncbi.nlm.nih.gov/pubmed/32066489
http://dx.doi.org/10.1186/s13063-020-4116-7

Ejemplares similares